key: cord-0430976-f29e0a1t
authors: S J, J.; Beegum, S.; Gopakumar, G.; G, B.; S, C.; Sasidharan, S.; Tonio, A.; REGHUKUMAR, A.
title: Prevalence of SARS CoV-2 infection among Health Care Workers of a hybrid tertiary COVID 19 hospital in Kerala
date: 2021-07-22
journal: nan
DOI: 10.1101/2021.07.19.21260792
sha: 282b93f56ebcfb05881cd5341d76365214af1166
doc_id: 430976
cord_uid: f29e0a1t

Back ground and objectives- This study was undertaken to estimate the prevalence of SARS-CoV-2 infection among Health care workers [HCWs] of a hybrid COVID treatment hospital in Kerala. Methods- The study was conducted during 3rd week of January 2021. Among 3550 HCWs, 979 subjects were selected by stratified random sampling and grouped into high risk and low risk category based on job setting. Demographic details and clinical information regarding previous history of COVID 19 were collected at the time of SARS-CoV-2 IgG testing. Results: From 979 subjects, the data with respect to 940 health care workers were analysed. SARS-CoV-2 IgG was detected in 19.1% of HCWs. Seroprevalence among high risk group was 20.3% and that in low risk group was 7.4% [p=0.005]. In high-risk group, seropositivity was noted in 30.54 % of nurses, 19% hospital attenders, 18.9% resident doctors and 6.4% consultant doctors. In those with past history of SARS-CoV-2 infection, seropositivity was 75.4%. In those who were COVID positive during July2020, 33.3% were still IgG reactive. Interpretation and conclusion- The study reported 19.1% SARS CoV-2 IgG reactivity among health care workers in our hospital. Seropositivity was significantly higher in high risk group compared to low risk group. Antibody decay kinetics in our study is comparable to that in published literature. Infection control challenges in hybrid hospitals account for higher seropositivity in this study compared to overall seroprevalence among HCWs in Kerala.

COVID 19 is a multisystem disease with predominant involvement of the respiratory system. COVID 19 transmission dynamics include droplet, contact and airborne transmission in specific settings. Health care workers are in close contact with COVID 19 patients, and so the probability of getting infected is very high as evidenced by studies from across the world. As around 40% of SARS-COV2 infections are asymptomatic, the exact prevalence among HCWs can be identified only by a seroprevalence study.

The first national population based serosurveillance study conducted by ICMR during May-June 2020, found that 0.73% of adults in India were exposed to SARS -COV2 infection [1] . SARS-COV 2 IgG seroprevalence study conducted by ICMR across three districts of Kerala in May, August and December 2020 showed prevalence of 0.33%, 0.73% and 11.6% respectively. The same survey showed that the seroprevalence in India during same time period was 0.8%, 6.60% and 21.50%. Majority of the studies from across the world have shown that seroprevalence among HCWs is higher than that in the community. This is because Health care workers (HCW] have more risk of exposure, and those working in critical care units are likely to have exposure to higher viral inoculum load from aerosol generating procedures which are inevitable. Risk of acqusition of HCW infection is higher in those who work in hybrid hospitals compared to that in designated COVID hospitals. This is because in hybrid hospitals both COVID and non-COVID cases are admitted where as in designated COVID hospitals only confirmed COVID 19 cases are admitted. Infection prevention and control is more challenging in hybrid hospitals than in designated COVID hospitals.

Seroprevalence among HCWs vary from hospital to hospital and depends on the stage of the pandemic in the district during the study period and infection control practices adopted in the hospital. In India, a study done among 25% of HCW of a tertiary care hospital had shown seroprevalence of 11.94% [2] . According to ICMR third round seroprevalence study, 25.7% of HCWs in India have COVID 19 antibodies. A study conducted during July 2020 among HCWs of a hospital in Kerala showed no prevalence of SARS COV-2 IgG [3] . But during the study period seroprevalence in Kerala was only 0.2%. There is no published study related to seroprevalence of COVID 19 among HCWs from a hybrid COVID hospital in Kerala after surge of cases occurred and population seroprevalence increased from 0.2 to 11.6%. This study was undertaken to estimate the prevalence of SARS-CoV-2 infection among HCWs of Government Medical College Thiruvananthapuram [GMCT], a hybrid tertiary care centre. Thiruvananthapuram district has reported maximum number of cases of COVID 19 in Kerala and had peak case load in October 2020. Eventhough the protective role of antibodies against SARs-CoV-2 is unknown; they can be taken as a correlate of antiviral immunity and may correspond to plasma viral neutralizing . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 22, 2021. ;

activity. Persistence and decay kinetics of SARS-CoV-2 IgG among HCWs needs to be studied in detail. 

Statistical analysis: -Numerical variables such as age, IgG values etc were presented as mean and standard deviation. Categorical variables such as sex, risk category of subjects, symptoms, co-morbidities and test results were presented as frequency and percentage. 95% CI of observed prevalence and true prevalence was adjusted for sensitivity and specificity of the reagent kit. The corresponding 95 % CI for adjusted prevalence was calculated by Blaker's method using R software. IgG reactivity among various categories of participants were analyzed by Chi square test. A two-sided probability value of <0.05 was considered statistically significant. Random sample numbers were generated and data analysis was performed Using R software (R version 3.6.2 (2019-12-12) Copyright (C) 2019 The R Foundation for Statistical Computing Platform: x86_64-w64-mingw32/x64 (64-bit)) and SPSS version 16.0.

The sample size calculated for the study was 979. Of this, 39 participants were excluded from the study due to incomplete proforma and so the final sample size was fixed at 940. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 22, 2021. ;

In the study SARS-CoV-2 IgG seropositivity was identified in 180 cases, resulting in an observed prevalence of 19.1%. Reagent sensitivity and specificity was 90% and 100% respectively. When 95% CI is adjusted for test sensitivity and specificity by Blaker΄s method, the true prevalence arrived at is 21.2%.

Out of the 940 study participants (Table 1) , 765 (81.4%) were below 50 years and 175(18.6%) were above 50 years of age. Sex ratio among study participants was 69.3% females and 30.6% males respectively. Past history of COVID test positivity and seropositivity-( Table 2 ).In the study, 134 participants had been tested positive by RTPCR in the past for SARS-CoV -2 infection. Among these 134 study subjects, 101 (75.4%) were SARS-CoV-2 IgG reactive. Of the 536 subjects who had tested COVID negative in the past, 51 (9.5%) were seropositive for SARS-CoV -2 IgG. In 270 subjects who had never undergone COVID test in the past, 28 (10.4%) were seropositive (p˂ 0.001} Prevalence as per age& sex- (Table 3 ) Seropositivity below 50 years was 19.3% (n=148) and above 50 years was 18.3 % (n= 32) with a p-value of 0.748 which is not statistically significant. Seropositivity among males and females were 14.9% and 21% respectively with a p value of 0.029 which is statistically significant. Seropositivity based on risk and job category-( Table 3) Among HCWs in High-risk group 20.3% (n= 174) and among low risk group 7.4% (n=6) were seropositive with a stastically significant p value of 0. 005. Among high-risk group, 6.4% of Doctors (n= 9), 18.9% residents (n=59), 30.54% of nurses(n=76) and 19% of attenders (n=30) were seropositive with a stastically significant p value ˂0.001.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 22, 2021. ;

In the low risk group, 11.5% of doctors, 5.1% of technicians and 6.3% of junior lab assistants were seropositive. Seropositivity and comorbidities - (Table 3 ) Among 180 seropositive subjects, 24.8% had atleast one comorbidity. Of them 22.9% were hypertensives, 25.9% were diabetic, 17.6% had coronary artery disease and 35.7% had bronchial asthma. Symptomatology in SARS-COV 2 IgG seropositive subjects - (Table 4) Of the subjects who were seropositive for SARS-COV-2 IgG , 41.5% had fatigue, 31.2% sore throat, 31.2% rhinorrhoea, 34.3% cough,72% fever, 69.6% anosmia, 78.3% ageusia, 60% vomiting, 25.7% diarrhea and 32.6% had atleast one of the above symptoms during the last 6 months. Symptomatology in subjects who had tested positive for COVID 19 and are seroreactive -In COVID tested positive subjects who were seroreactive 88% had cough, 87% sore throat, 86.1% anosmia, 85% ageusia, 81.4% fever, rhinorrhoea 80%, and 79.2% had fever at the time of diagnosis of COVID 19. Seropositivity among subjects detected to have COVID 19 in July, August, September, October, November and December were 33.3%, 73%,79.2%,87%,88.9% and 92.9% respectively. A low titre S/Co was present in 43.6% and medium titre S/Co was present in 56.4% of study subjects with past history of COVID 19 who were SARS-CoV-2 IgG reactive. None of the study subjects had a high titre S/Co. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 22, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 22, 2021. ; 

The relation between time since infection and antibody titre is shown in figure 2 . Antibody titre of subjects infected 6 months prior to testing showed 33% positivity with rates inversely proportionate to time from infection. At 1 month after infection, only one patient had negative titre. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 22, 2021. ;

When COVID Anitibody positivity titres were analyzed among symptomatic and asymptomatic groups, antibody titres showed a decrease with time from infection in both groups and are depicted in Figure 3 , 4 and 5.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 22, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 22, 2021. ; https://doi.org/10.1101/2021.07.19.21260792 doi: medRxiv preprint

Kerala was the first state in India to report COVID 19 case on January 29, 2020. First COVID 19 patient got admitted to GMCT on March 13 th . GMCT, a 3250 bedded tertiary care hospital, was converted to a hybrid COVID hospital catering to both non-COVID as well as patients with moderate and severe SARS-CoV 2 infection. Being a border district and due to multiple coastal clusters, Thiruvananthapuram district had the maximum number of cases in Kerala with epidemic peak in October, 2020. Till date more than 10000 COVID 19 patients have been admitted to GMCT and 936 health care workers have been diagnosed to have COVID 19. In a study done during May 2020 in Kerala, the prevalence of SARS-CoV 2 infection was only 0.5% among HCWs (technical paper, Kerala). At the time of the study, total number of cases in Kerala was around 1000 only. Seroprevalence of SARS-CoV 2 infection in Kerala which was 0.3% in August increased to 11.6% in December and during this period, a similar increase in COVID 19 among HCWs was noted.

The present study was conducted between 8 th January and 19 th January 2021.As on 19 th January, Kerala had a cumulative case load of 8,57,380 cases with 70,259 active cases. Our study showed a seropositivity of 19.1% among HCWs . A similar study done at National capital region of India conducted between January 12 th and February 13 th 2021 reported a seroprevalence of 46.2% among HCWs [4] . In India, the seropositivity among HCWs was 2.5% during June in Kashmir, 11% in Mumbai during May and 11.94% in Kolkata during July 2020 [5, 6, 3] . Lower seroprevalence among HCWs in these studies reflect the stage of the pandemic in respective states during the study period. The seropositivity among HCWs in other countries was 1.6%, 3.4% and 6% in Germany, Italy and England respectively [7, 8, 9] .This low prevalence of SARS-CoV-2 IgG antibodies reflects the burden of pandemic in the study population in the particular time window. In Kerala, COVID 19 peaked in October 2020 and the epidemic curve has plateaued ever since. Higher SARS-CoV -2 IgG seropositivity among HCWs observed in our study reflects the epidemic situation in the state in the months prior to study period and that is the reason why seropositivity among HCWs in our study is high. Interestingly in the seroprevalence study conducted by Government of Kerala in February 2021, seropositivity among HCWs was 10.5%.The high seropositivity among HCWs [19.1%] in GMCT compared to the average seropositivity among HCWs [10.5%] across the state reflects the infection prevention and control challenges in a hybrid hospital which caters to both COVID and non-COVID patients.

In this study statistically significant difference in seropositivity was observed among female HCWs [21%] compared to that in males [14.9%] . This is due to the greater representation of female nurses in high risk category subgroup who turned seropositive [ 30.54%] .Initial studies from China had reported a sex disparity in COVID 19 epidemiology, whereas global Health 50/50 research initiative has observed similar number of cases in men and women [10] .

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 22, 2021. ;

In our study, statistically significant difference in seropositivity [20.3%] is observed in high risk category compared to that in low risk category [7.4%] . This finding is consistent with a study done in Switzerland [11] . Among the subgroups of high risk category, seropositivity was higher in nurses [30.54%] followed by hospital attenders [19%] , resident doctors [18.9%] and consultant doctors [6.4%] . Nurses are at the highest risk of occupational exposure due to the nature of their work which results in longer duration and intensity of exposure to SARS-CoV-2.This is the reason why among HCWs in high risk category, nurses have maximum seropositivity. Consultant doctors have minimum duration of exposure to COVID 19 patients and that explains why seropositivity among them is only 6.4%.

In our study of the 180 subjects who were seropositive, only 24.8% had atleast one co-morbidity. This can be explained by the fact that 81.4% of study population was below 50 yrs of age. More over in our hospital, younger staff without co-morbidities were posted preferentially in high-risk areas. The practice of selectively posting those with co-morbidities in low risk areas in our institution probably helped in protecting them from getting infected.

The potential symptoms suggestive of COVID 19 in seropositive HCWs who had never tested for COVID 19 were analyzed in this study. Ageusia and anosmia were the common symptoms in that group. The predictive symptomatology for COVID 19in this study is similar to that in studies done in Sweden [12] and a multinational population-based cohort in US & UK [13] . In this study, in seropositive with past history of COVID 19 all the potential COVID 19 symptoms were present in more than 75% of subjects similar to a study done on health care personnel in Washington [14] .

In this study, of the 134 HCWs with past history of COVID 19, 75.4% were detected to be seropositive. SARS-CoV-2 IgG was tested by CLIA method. Different methods to measure SARS-CoV-2 IgG like ELISA, CLIA and rapid lateral flow immunoassay have been found to have equivalent clinical performance for detecting IgG 14 days after onset of symptom in certain studies. [15] . Whereas a systematic review and meta-analysis to determine diagnostic accuracy of serological tests for COVID 19 detection have found lower sensitivity for lateral flow immunoassay when compared to ELISA and CLIA [16] .

In this study, 75.4% of the subjects with past history of COVID -19 were seropositive for SARS-CoV-2 IgG. Antibody decay kinetics in our study assuming that all patients with past history of COVID 19 had developed IgG antibodies, is comparable to the rate of decay in published literature [17] . Even after six months of SARS-CoV-2 infection, 33.3% of patients had SARS-CoV-2 IgG antibody. The persistence of SARS-Cov-2 IgG in patients who were diagnosed to have COVID 19 at 5,4,3,2 and 1 month prior to the study period was 73% ,79.2% ,87% ,88.9% and 92.9% respectively. Initial studies on antibody decay kinetics in COVID 19 had shown that majority of the patients seroreverted by three months [17] . Similar antibody kinetics was . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 22, 2021. observed in another study performed on 271 lab confirmed SARS-CoV-2 infection [18] . Antibody persistence upto 4 months after infection has been observed in studies from Iceland and USA. Later studies done using more sensitive CLIA test kits have shown antibody persistence for more than 6 months of SARS-CoV-2 infection.

This study was done using VITROS Ig G KIT in which results are calculated as signal/Cut off (S/Co). A serosurvey study on convalescent plasma therapy in COVID19 at Mayo clinic using the VITROS IgG kit revealed value between 1.0-4.64 S/Co as low titer, 4.62-18.45 as medium titer and above 18.45 as high titer [19] . In our study 40.6% came in low titer and 59.4% a medium titer.

The seroprevalence of SARS-CoV-2 infection among HCWs in GMCT was found to be 19.1% in this study.

Seropositivity was significantly higher in high risk group compared to low risk group. Antibody decay kinetics observed in this study is comparable to that in published literature. Even after six months of SARS-CoV-2 infection, 33.3% of patients had SARS-CoV-2 IgG antibody. The persistence of SARS-Cov-2 IgG in patients who were diagnosed to have COVID 19 at 5,4,3,2 and 1 month prior to the study period was 73% ,79.2% ,87% ,88.9% and 92.9% respectively. The high seropositivity among HCWs [19.1%] in GMCT compared to the average seropositivity among HCWs [10.5%] across the state reflects the infection prevention and control challenges in a hybrid hospital which caters to both COVID and non-COVID patients.

findings from the second nationwide household serosurvey

Seroprevalence of COVID-19 Amongst Health Care Workers in a Tertiary Care Hospital of a Metropolitan City from India

SARS-CoV-2 antibodies in healthcare workers in a large university hospital

Is Covid-19 seroprevalence different in health care workers as per their risk of exposure? A study from a tertiary care hospital in National Capital Region of India

SARS-CoV-2 seroprevalence in healthcare workers of dedicated-COVID hospitals and non-COVID hospitals of District Srinagar

Prevalence and Clinical Presentation of COVID-19 among Healthcare Workers at a Dedicated Hospital in India

Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19 . The COVID-19 resource centre is hosted on Elsevier Connect , the company ' s public news and information

COVID-19 among healthcare workers in a specialist infectious diseases setting in Naples, Southern Italy: results of a cross-sectional surveillance study

SARS-CoV-2 antibody screening in healthcare workers in a tertiary centre in North West England

Impact of sex and gender on COVID-19 outcomes in Europe

Risk assessment and seroprevalence of SARS-CoV-2 infection in healthcare workers of COVID-19 and non-COVID-19 hospitals in Southern Switzerland

SARS-CoV-2 exposure, symptoms and seroprevalence in healthcare workers in Sweden

Real-time tracking of self-reported symptoms to predict potential COVID-19

Symptom Screening at Illness Onset of Health Care Personnel with SARS-CoV-2 Infection in King County, Washington

Assessment of SARS-CoV-2 serological tests for the diagnosis of COVID-19 through the evaluation of three immunoassays: Two automated immunoassays (Euroimmun and Abbott) and one rapid lateral flow immunoassay (NG Biotech)

Diagnostic accuracy of serological tests for covid-19: Systematic review and meta-analysis

Disappearance of antibodies to SARS-CoV-2 in a -COVID-19 patient after recovery

Kinetics of severe acute respiratory syndrome (SARS) coronavirus-specific antibodies in 271 laboratory-confirmed cases of SARS

Effect of convalescent plasma on mortality among hospitalized patients with COVID-19: Initial three-month experience